What we do
The pharmaceutical industry and patient organisations have worked together for many years to advocate for policies that benefit patients. Commitments to shared goals have led to policy changes such as:
- faster and fairer access to ground-breaking medicines
- increased prioritisation for chronic disease areas in national strategies and plans
Raising understanding of the needs of patients with rare diseases and increasing patient involvement in clinical research.
Building on these strong foundations, we will continue to involve patient organisations in our policies and campaigns as they are being developed.
We will do so in a way that is appropriate to the topic in question and works for the organisations involved, respecting their capacity and other priorities.
We will also continue to integrate our patient involvement commitment into the ABPI strategy to ensure it is considered and integral in all our strategic priorities.